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ABSTRACT  
Rationale:  The acute respiratory distress syndrome is refractory to pharmacological 
intervention.  Inappropriate activation of alveolar neutrophils is believed to underpin this 
disease’s complex pathophysiology, yet these cells have been little studied.  
Objectives:  To examine the functional and transcriptional profiles of patient blood and 
alveolar neutrophils compared to healthy volunteer cells, and define their sensitivity to 
phosphoinositide 3-kinase inhibition. 
Methods:  Twenty three ventilated patients underwent bronchoalveolar lavage.  Alveolar and 
blood neutrophil apoptosis, phagocytosis and adhesion molecules were quantified by flow 
cytometry, and oxidase responses by chemiluminescence.  Cytokine and transcriptional 
profiling utilized multiplex and GeneChip arrays.   
Measurements and Main Results:  Patient blood and alveolar neutrophils were distinct from 
healthy circulating cells, with increased CD11b and reduced CD62L expression, delayed 
constitutive apoptosis and primed oxidase responses.  Incubating control cells with disease 
bronchoalveolar lavage recapitulated the aberrant functional phenotype and this could be 
reversed by phosphoinositide 3-kinase inhibitors.  In contrast, the pro-survival phenotype of 
patient cells was resistant to phosphoinositide 3-kinase inhibition.  RNA transcriptomic 
analysis revealed modified immune, cytoskeletal and cell death pathways in patient cells, 
aligning closely to sepsis and burns data sets but not phosphoinositide 3-kinase signatures. 
Conclusions:  Acute respiratory distress syndrome blood and alveolar neutrophils display a 
distinct primed, pro-survival profile and transcriptional signature.  The enhanced respiratory 
burst was phosphoinositide 3-kinase-dependent, but delayed apoptosis and the altered 
transcriptional profile were not.  These unexpected findings cast doubt over the utility of 
phosphoinositide 3-kinase inhibition in acute respiratory distress syndrome and highlight the 
importance of evaluating novel therapeutic strategies in patient-derived cells. 
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INTRODUCTION 
The acute respiratory distress syndrome (ARDS) is characterised by diffuse alveolar injury 
and immune cell infiltration, resulting in intractable hypoxemia [1].  Despite the adoption of 
lung-protective ventilation, mortality remains high [2], and many survivors suffer long-term 
physical or neurocognitive sequelae, with fewer than 50% returning to work [2].  
Management remains largely supportive with optimisation of ventilator parameters [3], 
judicious fluid balance, and treatment of underlying causes; no pharmacological interventions 
have proven beneficial. 
 
Accumulation of neutrophils (PMNs) in the lung microvasculature, interstitial and alveolar 
compartments is a key feature of ARDS [4], and association has been reported between 
intensity of alveolar neutrophil infiltration and disease severity [5].  Inappropriate 
accumulation/activation of PMNs within the alveoli is proposed to cause unrestrained release 
of oxygen radicals, proteases and neutrophil extracellular traps (NETs).  Due to challenges 
inherent in isolating alveolar PMNs (alvPMNs), their functional activity in ARDS is largely 
unknown.  Historically, mouse models have been used as surrogates for alvPMNs [6]; 
however, rodent neutrophils differ markedly from their human counterparts. 
 
Traditionally PMNs have been viewed as a homogenous population of short-lived cells with 
limited transcriptional capacity and a fixed functional repertoire.  More recently, concepts of 
long-lived PMNs, retrograde trans-endothelial migration and PMN plasticity have emerged 
[7-12].  Given recent demonstrations that PMNs can modify their transcriptional profile 
following an inflammatory insult [13], genome-wide transcriptional analysis provides a 
powerful tool to identify novel targets relevant to altered PMN functions, and has been 
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successfully applied in asthma, pulmonary arterial hypertension and ARDS [14]; however, 
studies in ARDS are based on the analysis of total peripheral white blood cells rather than 
purified neutrophils. 
 
Lung epithelial cells [15] synthesize granulocyte macrophage-colony stimulating factor (GM-
CSF), a cytokine essential for alveolar macrophage function [16-17] and surfactant 
homeostasis [18-19].  Conversely, during inflammation GM-CSF potentiates superoxide-
anion production [20], promotes PMN survival [21], and is detrimental in models of acute 
lung injury [22]. PMN longevity increases dramatically in ARDS, and some studies have 
identified GM-CSF as a major pro-survival mediator [23].  Whilst the molecular mechanisms 
governing PMN lifespan in ARDS are incompletely understood, the cytoprotective effect of 
GM-CSF in PMNs in vitro is Class 1 phosphoinositide 3-kinase (PI3K)-dependent [21].  
PI3K inhibition prevents lung tissue edema and leukocyte recruitment in models of ARDS 
[24], and inhibition of PI3Kγ in a sepsis model reduces end-organ damage [25].  Following 
the early exuberant pro-inflammatory response in ARDS, patients develop immune-paresis, 
increasing susceptibility to nosocomial infections [26]; recent studies demonstrate that 
inhibition of PI3Kδ may improve PMN responses during this phase [27].  These observations 
have triggered considerable interest in the therapeutic use of PI3K inhibitors in ARDS.  
 
Herein we present the first comprehensive characterization of purified ARDS blood 
(bloodPMN) and alvPMNs and the first genome-wide transcriptome analysis of purified ARDS 
bloodPMNs.  We show that ARDS alvPMNs are hyper-segmented, with enhanced CD11b and 
reduced CD62L expression, and display delayed apoptosis but preserved oxidative burst, 
phagocytosis and neutrophil extracellular trap (NET) responses.  ARDS bloodPMNs display an 
intermediate phenotype, with a transcriptome showing significant alterations in cell-survival 
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and inflammatory pathways, but little overlap with the PI3K-dependent gene signature.  This 
work improves our understanding of PMN function in ARDS and reveals that apoptosis of 
ARDS neutrophils is resistant to PI3K inhibition.  Together, these observations strengthen the 
case to modulate PMN function in ARDS, but cast doubt over the utility of PI3K inhibitors in 
this condition.		Some results from these studies have been reported in the form of an abstract 
[28]. 
 
MATERIALS and METHODS 
Ethics  
All studies complied with the Declaration of Helsinki.  Written informed consent was 
obtained from the legal surrogate of ARDS patients (UK08/H0306/17).  Paired blood samples 
were obtained simultaneously from age and gender matched healthy volunteers (HV) 
(UK06/Q0108/281).  
 
Bronchoalveolar lavage 
Patients fulfilling the Berlin criteria for ARDS [29] were recruited from mixed 
medical/surgical and neurosciences/trauma intensive care units in a UK teaching hospital; 
exclusion criteria were age <18 years, HIV positive, or if informed assent could not be 
obtained.  The median tidal volume in the ARDS patients was 7.64 ml per kilogram Predicted 
Body Weight (IQR=6.94-8.64 ml/kg).  Patients underwent venepuncture, bronchoscopy 
(FOB) and bronchoalveolar lavage (BAL) within 48 hours of diagnosis.  Sterile isotonic 
saline (3x50 ml) was instilled into a sub-segmental bronchus; recovery averaged 90 ml (range 
20-120 ml) and did not differ between patients and controls.  BALF was immediately filtered 
and placed on ice.  Control BALF was collected from patients (n=10) undergoing elective 
FOB for indications unrelated to infection or ARDS. 
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PMN purification 
alvPMN and autologous bloodPMN were isolated from patients alongside bloodPMN from age 
and gender-matched HVs.  Alveolar PMNs were purified by immune-magnetic negative 
selection (RoboSep→, StemCell Technologies) [30] to >90% purity and >98% viability.  
bloodPMNs were purified over discontinuous plasma-Percoll gradients [28]. 
 
PMN morphology 
PMN were classified by nuclear morphology, with the assessor blinded to sample origin.  
Mature PMN displayed 3-4 nuclear lobes connected by heterochromatin filaments.  Band 
PMNs had less condensed chromatin and incompletely segmented nuclei [31], whilst hyper-
segmented PMNs possessed ≥5 lobes. 
 
PMN activation and apoptosis 
HV and ARDS bloodPMNs and unprocessed BALF were re-suspended in PBS containing 5% 
BSA and protease inhibitor cocktail (Complete Mini EDTA-free, Roche).  Samples were 
stained with CD62L-APC (BD Pharmingen-clone 559772), CD11b-FITC (Beckman Coulter 
clone IM0530) or isotype-matched controls.  PMN apoptosis was assessed after 20 hours by 
flow cytometry using FITC-labelled Annexin-V/propidium iodide (AnV/PI, BD-
Pharmingen). 
  
PMN oxidative burst 
Neutrophils (5x106/mL) were primed with tumor necrosis factor (TNF)-α (R&D Systems), 
GM-CSF, control BALF or ARDS BALF at 37°C for 30 minutes.  The oxidative burst in 
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response to fMLP (100 nM), zymosan or heat-killed Streptococcus pneumoniae (serum-
opsonized, 5-7 particles/PMN) was assessed by luminol-dependent chemiluminescence [30]. 
 
Quantification of inflammatory mediators  
BALF and serum mediators were measured by ELISA (LPS (Kamiya), survivin and LTB4 
(R&D Systems)), or using the Human Biomarker 40-Plex V-PLEX Kit and Human MMP 3-
Plex Ultra-Sensitive Kit (MesoScale Discovery).  Where stated BALF samples were 
corrected to the total protein concentration (Pierce™ BCA-Protein Assay). 
 
PMN phagocytosis 
PMN phagocytic capacity was assessed using 1 mg/ml pHrodo™ RED Staphylococcus 
aureus Bioparticles® (Life Technologies).  Internalization was verified by live confocal 
imaging. 
 
NET formation 
bloodPMNs and alvPMNs (1x106/ml) incubated with Sytox Green (5 µM, Life Technologies) 
were seeded onto 96 well optical microplates (BD Biosciences).  NET formation was 
quantitated by hourly fluorescence measurements and verified by fluorescence microscopy 
using rabbit anti-histone H3 (Ab5103, Abcam). 
 
Neutrophil cytoskeletal remodelling 
Freshly isolated PMNs (1 x106/ml) were fixed (4% PFA), permeabilized (0.5% Triton) and 
stained with anti-neutrophil elastase (Santa Cruz, 1:1,000) and rhodamine phalloidin 1:200 
(Invitrogen). 
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Genome-wide transcriptomic changes 
Genome-wide transcriptomic changes were assessed in paired blood PMNs from n=12 
consecutively recruited ARDS patients, who were representative of the full patient cohort in 
terms of age, gender, ARDS severity and causation, and n=12 HVs.  Further studies were 
undertaken in the following groups of HV bloodPMNs (n=10/group): (a) T=0 hours vehicle 
control, (b) T=6 hours vehicle control, (c) T=6 hours rhGM-CSF (1 ng/ml), (d) T=6 hours 
panPI3K inhibitor ZSTK474 (10 µM), and (e) T=6 hours rhGM-CSF plus ZSTK474. 
 
cDNA prepared from 2.5 ng RNA using WT-Ovation Pico RNA Amplification System 
(NuGen) was fragmented and labelled using FL-Ovation cDNA Biotin Module V2 (NuGen).  
Labelled cDNA was hybridized onto Hg-U133 Plus 2.0 GeneChip oligonucleotide arrays 
(Affymetrix).  Raw data (see ‘Additional Materials’ supplement’) were normalised using the 
Robust Multi-array Average (RMA) method [32] and Quality Checked in R/Bioconductor.  A 
linear model was fitted to normalised data for each probe set and a post-hoc test (Fisher LSD) 
generated fold changes and p-values.  Probes were identified as significant if their fold 
change was >1.5 and p<0.05, and mapped to pathways using Ingenuity Pathway Analysis 
software.  The NextBio analysis platform was used to compare our ARDS data with (pre-
analysed) publicly available transcriptomics data. 
 
Statistical analysis 
For each dataset analysed an appropriate linear mixed model was fitted.  When required the 
data were logarithmically transformed to meet the assumptions of the analysis i.e. normally 
distributed errors and homogeneity of variance.  Correction for false discovery rates in the 
transcriptional and cytokine analysis was according to the method of Benjamini and 
Hochberg [33].  The analyses were conducted in SAS version 9.3.  Results are presented as 
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means ± SEM of (n) independent experiments, with p<0.05 considered statistically 
significant.  Full details of the number of patients and HVs included in each assay are 
provided in Suppl Figure S1. 
 
RESULTS 
ARDS patient characteristics 
Twenty-three mechanically ventilated patients fulfilling the 2011 Berlin definition for ARDS 
were recruited; their clinical, demographic and physiological characteristics are outlined in 
Table 1.  Standardized ventilator strategies, in accordance with the ARDS Network low tidal 
volume protocol, were employed.  At sample collection, 4/23 had severe ARDS (PaO2/FiO2 
ratio ≤100 mmHg), 11/23 moderate ARDS (PaO2/FiO2 ratio 101-200 mmHg) and 8/23 mild 
ARDS (PaO2/FiO2 ratio 201-300 mmHg).  Sepsis and pneumonia were the commonest 
precipitating insults; 13 of 23 patients survived to discharge.  All patients underwent FOB 
within 48 hours of diagnosis.  PMNs constituted 69.7±4.2% of the differential leukocyte 
count in ARDS BALF (6.5±3.2% in control BALF) (Table 1).  PMN abundance in BALF did 
not correlate with initial ARDS severity, abnormalities in gas exchange or BALF protein 
concentration (data not shown).  
 
ARDS PMNs are phenotypically distinct 
Comparing purified HV bloodPMNs, ARDS bloodPMNs and alvPMNs revealed striking 
differences in cell morphology.  While HV bloodPMNs had few hyper-segmented PMNs, 
alvARDS PMNs displayed abundant hyper-segmented nuclei and cytoplasmic vacuolation 
(Figure 1A); hyper-segmented PMNs were not identified in control BALF.  Immature ‘band’ 
PMNs were also more common in ARDS bloodPMNs and alvPMNs (Figure 1A).   
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PMN activation status was assessed by confocal imaging of F-actin and cell surface staining 
of CD62L (L-selectin) and CD11b (Mac1).  Prominent circumferential F-actin fluorescence 
was observed in a substantial proportion of the ARDS bloodPMNs compared with HV 
bloodPMNs (Figure 1B). The profile of surface receptor expression (up-regulation of CD11b 
and down-regulation of CD62L [36-37]) on both ARDS bloodPMNs and alvPMNs is consistent 
with a primed and/or activated phenotype (Figure 1C). 
 
ARDS blood and alveolar PMNs show delayed apoptosis and primed NADPH oxidase 
responses 
Consistent with a previous report [23], we demonstrate that after 20 hours ex-vivo incubation, 
ARDS alvPMNs and bloodPMNs demonstrated a significantly reduced number of apoptotic 
cells (28.5±19.2% (% apoptosis ± SEM) and 42.7±23% respectively) compared to PMNs 
isolated from HV blood (69.2±12%) (Figure 2A).  The magnitude of the survival response 
exhibited by ARDS PMNs was equivalent (28.6±10%) to the cytoprotective effect conferred 
by incubating HV bloodPMNs with a maximally-effective concentration of rhGM-CSF (1 
ng/ml) (data not shown). 
 
We next compared the ability of ARDS alvPMNs and bloodPMNs to mount an oxidative burst 
in response to fMLP, opsonized zymosan and Streptococcus pneumoniae (Figure 2B-D).  In 
contrast to un-primed HV bloodPMNs, which display minimal ROS generation to fMLP 
(Figure 2B-C), alvPMNs and bloodPMNs from ARDS patients displayed robust ROS 
generation to all three stimuli, which in certain individuals exceeded those of TNFα-primed 
HV bloodPMNs (Figure 2D).  These data indicate basal priming and preserved NADPH 
oxidase responses of ARDS alvPMNs and bloodPMNs, challenging the notion that 
inflammatory PMNs become ‘exhausted’ at peripheral sites. 
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ARDS blood and alveolar PMNs have preserved capacity for phagocytosis and NET 
formation 
Previous investigators have identified a defect in the phagocytic and microbicidal activity of 
neutrophils from ARDS patients [38].  However, in our cohort, flow cytometry and confocal 
microscopy demonstrated that the capacity of ARDS alvPMNs and bloodPMNs to phagocytose 
pHrodo™ RED-labelled Staphylococcus aureus was fully preserved (Figure 3A-B).  This 
assay, supported by live cell imaging, is based on differential fluorescence of this bioparticle 
in an acidic environment, ensuring that only organisms within functional phagosomes are 
detected. 
 
In addition to phagocytosis and the oxidative burst, PMNs deploy NETs to facilitate pathogen 
clearance.  NETs are composed principally of a DNA scaffold decorated with anti-microbial 
granule proteins, which acts as a mesh to immobilize pathogens (Figure 3C).  In response to 
PMA (Figure 3 C-D) or pyocyanin (data not shown) ARDS alvPMNs and bloodPMNs 
displayed a similar capacity for NET production compared to HV bloodPMNs.  Collectively, 
our results, demonstrate preservation of the anti-microbial functions of ARDS alvPMNs and 
bloodPMNs. 
 
Defining the impact of ARDS on serum/BALF cytokine profiles and the transcriptional 
signatures of blood PMNs 
To address whether factors present in the serum or BALF in ARDS patients could account for 
the primed/pro-survival PMN phenotype, a series of multiplex ELISA and bioassays were 
used to characterize the cytokine and growth factor profiles (n=18).  As shown in Figure 4 
and Suppl Figure S2, a consistent profile of raised acute phase markers (e.g. CRP, SAA) and 
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inflammatory cytokines (e.g. TNFα, TARC, MCP-1, IL-8 and IL-6) was observed in ARDS 
serum and BALF compared to HV samples.  By contrast, when BALF samples were 
corrected for total protein concentration, only CRP, IL-6 and MCP-1 levels were significantly 
higher in ARDS compared to control (Suppl Figure S2).  Of note, at the single time point 
sampled, GM-CSF was only quantifiable in 5/23 ARDS BALF samples (LLoQ 7.6 pg/ml). 
 
RNA transcriptomic analysis comparing freshly isolated ARDS bloodPMNs with HV 
bloodPMNs revealed a total of 1319 altered genes (using cut-offs of fold-change >1.5 and 
p<0.05; top ranked up- and down-regulated transcripts shown in Figure 5A; full list of all 
1319 genes and their relative fold changes in Suppl Table S3).  Using NextBio (which 
recognised 1282 of the 1319 differentially expressed genes) we compared these changes to 
publically available datasets, revealing a striking similarity to data in leukocytes from 
patients with severe burns or sepsis [39-40]; not only was there a strong overlap in gene 
changes, but also the direction of change correlated almost completely (Figure 5B).  
Ingenuity analysis revealed a significant increase in pathways associated with the immune 
response, cytoskeletal remodelling and mucin production, as well as significant decreases in 
cell death/apoptosis pathways, consistent with the neutrophil phenotype observed (Suppl 
Figure S3).  Of note, of the 1319 observed transcript changes, only 216 were differentially 
expressed in the same direction compared to HV bloodPMNs treated ex-vivo with GM-CSF 
(Suppl Figure S4).  The data discussed in this publication have been deposited in NCBI's 
Gene Expression Omnibus and are accessible through GEO Series accession number 
GSE76293 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76293). 
 
Influence of the local airway environment on the ARDS PMN phenotype 
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To establish the significance of the alveolar inflammatory environment, we sought to induce 
a phenotypic switch using ARDS BALF.  Incubating HV bloodPMNs with IMDM+10% 
autologous serum containing ARDS BALF (50:50, v/v) reduced the extent of apoptosis 
observed ex-vivo at 20 hours (37.4±21.7% compared to 50:50, v/v control BALF 
70.5±12.4%) (Figure 6A).  Furthermore, treatment with ARDS BALF (50:50, v/v) for 30 
minutes enhanced fMLP-induced ROS production in HV bloodPMNs (Figure 6B), to a level 
comparable to optimally TNFα- or GM-CSF-primed HV bloodPMNs (not shown), whilst 
control BALF had little effect.  Thus ARDS BALF supernatant recapitulated the pro-survival, 
primed-NADPH oxidase signature seen in ARDS blood/alvPMNs. 
 
Potential role of PI3K inhibition as a strategy to modulate ARDS blood/alv PMN behaviour 
A key objective of this study was to define the sensitivity of inflammatory PMNs to PI3K 
inhibition, since this pathway is pivotal in neutrophil survival, priming/activation and reactive 
oxygen species (ROS) production [30].  Firstly, we confirmed that a pan-PI3K inhibitor 
ZSTK474 (10 µM) [41], and to a lesser extent the p38MAPK inhibitor SB741445 (10 µM) 
blocked GM-CSF-induced PMN survival in HV bloodPMNs in vitro (Figure 7A).  ZSTK474 
also blocked the survival effect of ARDS BALF supernatant on HV bloodPMNs (Figure 7B).  
However, neither compound restored normal neutrophil apoptosis in ARDS bloodPMNs 
(Figure 7C) implying that the aberrant disease-associated neutrophil survival is either 
irreversible or operates through a PI3K-independent pathway.  Given that even the delayed 
addition of ZSTK474 to GM-CSF-treated HV bloodPMNs retains effectiveness in overcoming 
the pro-survival effect of this cytokine (data not shown), the involvement of a PI3K-
independent pathway seems most likely.  This conclusion is supported by the minimal 
overlap we observed between the transcriptomal signatures seen in the ARDS bloodPMNs and 
those seen in HV bloodPMNs treated with ZSTK474 (Suppl Figure S5).  In contrast, ROS 
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production by PMNs from HV and ARDS patients was completely abrogated by ZSTK474 
(Figure 7D). 
 
DISCUSSION 
Isoform-selective PI3K inhibitors have been proposed as anti-inflammatory agents in diseases 
such as ARDS [42], hence it is of importance to study their efficacy in patient-derived cells.  
ARDS alvPMNs have been little studied due to the difficulty of obtaining these cells from 
acutely unwell patients.  Using purified blood and alveolar neutrophils from 23 ARDS 
patients, we demonstrate a stepwise change from HV bloodPMNs through ARDS bloodPMNs to 
ARDS alvPMNs.  ARDS alvPMNs, and to a lesser extent ARDS bloodPMNs, were distinct from 
HV bloodPMNs, with hyper-segmented nuclei, increased CD11b expression, prolonged 
survival, and primed NADPH oxidase responses.   Surprisingly, whilst the respiratory burst 
remained fully sensitive to PI3K inhibition, the pro-survival phenotype was not reversed by 
this strategy. 
 
Few previous studies have assessed the characteristics of paired circulating and post-migrated 
inflammatory tissue neutrophils.  The hyper-segmented CD11bhigh/CD62Llow cells with 
enhanced oxidative capacity we identify in ARDSblood and ARDS alvPMNs are reminiscent of 
circulating neutrophils isolated following endotoxin challenge [43-44]; these latter cells were 
immunosuppressive, inhibiting T cell proliferation by release of hydrogen peroxide at the 
neutrophil/T cell interface.  Increased nuclear segmentation and oxidative potential has also 
been observed in tumor-associated neutrophils (45), associated with increased anti-tumor 
activity.  Prolonged survival of ARDS alvPMNs has been reported previously and attributed to 
GM-CSF/G-CSF in BALF [23], but in contrast to Matute-Bello et al we did not observe 
significantly elevated levels of these cytokines, perhaps related to disease heterogeneity and 
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differences in sampling time.  Delayed apoptosis has been measured in neutrophils recruited 
to skin chambers versus paired circulating neutrophils, but synovial fluid-derived PMNs from 
patients with rheumatoid arthritis exhibited normal apoptosis [46].  These differences 
correlated with local IL1-β levels, but IL1-β in our ARDS BALF fluid was not significantly 
elevated.  The variable functional capacity of neutrophils from different locations underscores 
the need to explore the efficacy of potential therapeutic agents in disease-relevant cell 
populations.  
 
We observed a pro-inflammatory cytokine profile in the blood of ARDS patients, including 
several established priming agents.  In our study, ARDS blood and ARDS alvPMNs were 
functionally primed, and such cells have been implicated in lung injury [47-48].  We 
previously demonstrated that the pulmonary capillary bed can trap and 'de-prime' neutrophils, 
and that this mechanism may fail in ARDS, augmenting the circulating pool of these 
potentially injurious cells [49].  Additional priming signals may be imparted during vascular 
transmigration [50], and ARDS BALF also primed the oxidative burst of HV bloodPMNs.  
Thus a number of different factors may contribute to the pooling of primed neutrophils within 
the alveolar environment in ARDS. 
 
ARDS bloodPMNs and in particular ARDS alvPMNs survived longer during ex-vivo culture 
than HV bloodPMNs.  This pro-survival phenotype was recapitulated by incubating HV 
bloodPMNs with ARDS BALF, implying that the enhanced longevity of these cells results at 
least in part from local exposure to mediators. However, whilst the pan-PI3K inhibitor 
ZSTK474 did not reduce the lifespan of ARDS bloodPMNs it did reverse the pro-survival 
effects of both GM-CSF and BALF on HV bloodPMNs in culture, suggesting that the complex 
cytokine environment in BALF is not the only factor conferring PI3K-resistance. It is 
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possible that the duration of exposure to pro-survival mediators in vivo prior to inhibitor 
exposure is relevant, and survival signals imparted during transmigration will likewise have 
been entrained prior to PI3K inhibition.  Finally, hypoxia may impart additional signals that 
are also relatively PI3K-resistant, and HIF-dependent signalling was up-regulated (see Suppl 
Table 3 - ranked 14th in the pathways changed in this setting).  Together with the limited 
overlap between the ZSTK474 bloodPMN or GM-CSF-bloodPMN transcriptomes and the ARDS 
bloodPMN signature, our results suggest that targeting of PI3K during ARDS, while 
suppressing the damaging ROS formation, would not enhance cell clearance via apoptotic 
pathways. 
 
We further interrogated the activation state of ARDS bloodPMNs by undertaking the first 
reported transcriptomic analysis of purified peripheral blood PMNs from ARDS patients.  
Our data revealed remarkable overlap between the transcriptomic profile of ARDS bloodPMNs 
and those published for mixed leukocytes in burns (see Figure 4B) and sepsis cohorts [34-
35].  The top five canonical pathways identified in the ARDS blood neutrophil gene signature 
were the glucocorticoid, IL-4, p38 MAPK, antigen presentation and CDC52 pathways.  These 
were also within the top five pathways identified in the previous burns and sepsis cohorts 
using mixed leukocytes [39-40].  This suggests that despite their heterogeneity, there is a 
strong commonalty in a range of acute severe inflammatory disorders.  This also provides 
possible directions for novel therapeutic interventions aimed for example at the IL-4 receptor 
or p38 pathways. 
 
In this study we sought to characterise the functional and transcriptional profile of PMNs 
isolated from ARDS patients’ blood and airways.  Although our study captured only 23 
patients at a single time point, our data add considerably to knowledge of alvPMN and 
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bloodPMN function and signaling profiles in ARDS; they challenge data from both animal 
models and from healthy cells, with a marked primed and pro-survival phenotype, the latter 
recalcitrant to PI3K inhibition.  We conclude that intervention with a PI3K inhibitor in these 
patients is unlikely to be an effective therapeutic strategy, since it will impair PMN 
bactericidal function without facilitating inflammation resolution.  Our findings highlight the 
importance of working with patient-derived cells, particularly for biomedical research into 
novel treatments for ARDS. 
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FIGURE LEGENDS 
Table 1 
Clinical characteristics of patients with ARDS 
 
Figure 1  
Circulating and alveolar neutrophils from patients with ARDS are phenotypically 
distinct compared to healthy volunteer neutrophils 
A. Morphology of freshly purified PMNs from HVs in comparison with ARDS blood and 
alveolar PMNs was assessed.  Representative photomicrographs of cytospins (x100, stained 
with modified Wright stain) of HV bloodPMNs, and autologous alvPMNs and bloodARDS PMNs 
isolated in parallel (n=19).  Classical PMNs have 3-4 nuclear lobes connected by filaments of 
dense heterochromatin, band PMNs (red arrow) contain a curved nucleus that is not 
completely segmented into lobes, and hyper-segmented PMNs (black arrow) have nuclei 
comprised of five or more lobes.  ARDS BALF contains abundant hyper-segmented PMNs 
with up to 12 nuclear lobes (inset).  PMN subsets present in the blood (HV n=19; ARDS 
n=19) and ARDS BALF (n=11) were quantitated morphologically by light microscopy (right-
hand panel).  The %PMN subsets were analyzed on the log10 scale using a linear fixed effects 
model (*** P<0.0001 for hyper-segmented cells).  B. HV bloodPMNs and autologous ARDS 
alvPMNs and bloodPMNs stained for F actin polarization (rhodamine-phalloidin – green) and 
elastase (red) with nuclei (DAPI) depicted in blue.  Representative (of n=3) 
immunofluorescence confocal photomicrographs (x40) illustrate ARDS alvPMNs and 
bloodPMNs display a prominent circumferential F actin ring (white arrows).  C. PMN cell 
surface CD62L-FITC and CD11b-APC expression of freshly isolated HV bloodPMNs, 
autologous ARDS alvPMNs and bloodPMNs assessed by flow cytometry.  Results are 
representative of three independent experiments.  The CD11b expression (MFI corrected for 
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isotype control readings) for HV blood neutrophils was 11.7±0.9, ARDS blood neutrophils 
74±6, and ARDS BALF neutrophils 427±50; the CD62L expression (MFI corrected for 
isotype control readings) for HV blood neutrophils 114±12, ARDS blood neutrophils 
8.4±0.6, and ARDS BALF neutrophils 8.7±1.9. 
 
Figure 2 
Circulating and alveolar neutrophils from patients with ARDS exhibit delayed 
apoptosis and heterogeneous NADPH oxidase responses  
A.  HV bloodPMNs (5×106/ml) were cultured in IMDM with 10% autologous 
serum.  Apoptosis was quantitated by flow cytometry following AnV staining after 20 hours 
in culture.  The data were analyzed using a linear fixed effects model (**P<0.001, 
***P<0.0001).  B.  Representative kinetic profile of the neutrophil oxidative burst.  Freshly 
purified HV bloodPMNs (unprimed-black squares and rhTNFα (10 ng/ml), primed-white 
squares), autologous ARDS alvPMNs (black circles) and bloodPMNs (white circles) were 
incubated with luminol and HRP in a 96-well luminometer plate and fMLP (100 nM) added 
via the injection port of a Centro LB 960 luminometer (Berthold Technologies); light 
emission (RLU) was recorded at 6 second intervals over 10 minutes.  C. The oxidative 
response in freshly isolated un-primed and rhTNFα-primed HV blood following stimulation 
with fMLP is expressed as the relative peak height to the rhTNFα-primed response in HV 
bloodPMNs.  D. Peak height of the neutrophil oxidative response in freshly isolated autologous 
ARDS alvPMNs and bloodPMNs normalised to the HV blood PMN response in Di to fMLP 
(100 nM), Dii to serum-opsonized zymosan (5-7 particles/PMN), and Diii to serum-
opsonized heat-killed Streptococcus pneumoniae (5-7 particles/PMN). 
 
Figure 3 
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Circulating and alveolar neutrophils from patients with ARDS exhibit preserved 
phagocytic capacity and heterogeneous NET responses 
A.  Analysis of phagocytosis by freshly isolated PMNs. Representative (of n = 5 
experiments) immunofluorescence confocal photomicrographs taken after 1 hour incubation 
demonstrating internalized pHRodo conjugated S. aureus (red) and PMN nuclei 
counterstained with DAPI (blue).  B.  PMN phagocytosis was quantitated by flow cytometry 
with fluorescence excitation 530 nm/emission 590 nm.  These data were analyzed using a 
linear fixed effect model (ns p>0.05).  C.  NET formation by freshly isolated autologous 
blood and alveolar ARDS PMNs and HV PMNs was assessed following treatment with PMA 
(20 nM) or vehicle control. Representative (n=4) fluorescence photomicrographs of NETs, 
x63 magnification. Unmerged images (lower panels) stained for extracellular DNA scaffold 
(SYTOX: green) and citrullinated histones (CitHis: red). The precise overlap of these two 
colors in merged images generates the ochre color representing NETS in the PMA-treated 
cells; no NETS are visible in the control samples.   D.  Kinetics of NETs formation was 
assessed over 4 hours by measuring total fluorescence using a VICTOR3 Multilabel Reader 
using Wallac 1420 Workstation v3.00 software and subtracting baseline fluorescence.  
 
Figure 4 
Heat map of the inflammatory markers in the serum of healthy volunteers and patients 
with ARDS 
Inflammatory mediators in serum were measured using either an ELISA kit or an 
electrochemical luminescence immunoassay MesoScale Discovery (MSD) multiplex.  In the 
heatmap each row is a different cytokine and each column is a different patient.  The coloring 
represents the abundance of the inflammatory marker measured.  The lowest abundance 
measured are presented by bright green while the highest by bright red.  To assess the mean 
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difference in abundance between the disease groups a linear mixed model was fitted to the 
data with disease as a fixed effect and the donor pairing as a random effect.		The heat maps 
and dendrogram (variable tree) were obtained from a hierarchical clustering of the cytokines 
using complete linkage.  The variable tree to the left of the heat map shows how the cytokines 
cluster together based on their Pearson’s correlation i.e., the more correlated two cytokines 
are the closer they are in the branches of the dendrogram.  The stars on the plot represent the 
FDR adjusted p-value of the disease effect in this model where NS=FDR p>0.05, *=FDR p 
<0.05, **=FDR p< 0.001 and ***=FDR p< 0.0001. 
 
Figure 5  
Genes altered greater than 5-fold in ARDS blood neutrophils compared to healthy 
volunteer blood neutrophils 
A. Negative values indicate a decrease in relative gene expression, while positive values 
indicate an increase in relative gene expression. All p<0.05 with (n) = 12 for ARDS and HV 
blood PMNs.  B. Diagrammatic representation of gene transcript changes between ARDS and 
HV blood PMNs and the overlap in the ARDS transcript signature with pediatric early stage 
burn data [39]. 
 
Figure 6 
Treatment of healthy volunteer blood neutrophils with BALF from patients with ARDS 
replicates the pro-survival and primed neutrophil phenotype 
A. HV PMNs were incubated in IMDM+10% autologous serum containing either 50:50 v/v 
control BALF or ARDS BALF and apoptosis was assessed at 20 hours by flow cytometry 
following AnV staining.  These data were analyzed using a linear mixed effects model with 
the HV donor fitted as a random effect (ns P>0.05, ***P<0.0001).  B. Freshly isolated HV 
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PMNs were treated with 50:50 v/v control BALF or ARDS BALF for 30 minutes at 37oC 
prior to stimulation with fMLP (100 nM). Chemiluminescence was recorded using a Centro 
LB 960 luminometer and expressed graphically as the absolute peak height in relative light 
units (RLU).  These data were analysed on the log10 scale using a linear mixed effects model 
with the HV donor fitted as a random effect (ns P>0.05, ***P<0.0001). 
 
Figure 7 
Effects of PI3K and p38 MAPK inhibition on healthy blood and ARDS neutrophils 
A.  HV blood PMNs were pre-incubated with either 0.1% DMSO vehicle control, p38 MAPK 
inhibitor (SB741445 (10 µM)) or pan-Class I PI3K inhibitor (ZSTK474 (10 µM)) for 20 mins 
and then treated with rhGM-CSF (1 ng/ml). Apoptosis was quantitated after 20 hours in 
culture by flow cytometry following AnV and PI staining.  These data were analyzed using a 
linear mixed effects model with the HV donor fitted as a random effect (***P<0.0001).  B.  
HV blood PMNs were pre-incubated with the indicated inhibitors for 20 mins prior to culture 
in 50:50 v/v ARDS BALF. Apoptosis was quantitated after 20 hours in culture by flow 
cytometry following AnV and PI staining.  These data were analyzed using a linear mixed 
effects model with the HV donor fitted as a random effect (ns P>0.05, **P<0.001).   C.  
ARDS blood PMNs were incubated with SB741445 or ZSTK474 and apoptosis was 
quantitated by flow cytometry following AnV and PI staining.  These data were analyzed 
using a linear mixed effects model with the HV donor fitted as a random effect (ns P>0.05, 
*P<0.05).  D.  ARDS blood and alveolar PMNs were pre-incubated with ZSTK474 (10 µM) 
for 30 minutes at 37oC prior to stimulation with fMLP (100 nM). Chemiluminescence was 
recorded using a Centro LB 960 luminometer and expressed graphically as the absolute peak 
height in relative light units (RLU). Data were analysed on the log10 scale using a linear 
mixed effects model with the HV donor fitted as a random effect (* P<0.05, ***P<0.0001). 
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Table 1.   Demographics and clinical characteristics of patients with ARDS
ARDS 
Mild Moderate Severe 
Number of patients 8 11 4 
Mean age (years) 49±16.3 62.7±11.1 48.3±21.0 
Gender 
(Male:Female) 
7:1 5:6 3:1 
Patient mortality (n) 2 7 2 
PaO2 (mmHg) 92.2±17.6 82.4±16.8 68.4±2.3 
Mean PaO2/FiO2 
(mmHg) 
246.1±18.9 139.5±18.8 90.0±5.7 
PEEP (cmH2O) 8.9±2.1 8.9±2.6 8.5±1.9 
Blood WBC  11.1±10.1 10.8±8.0 12.9±8.4 
Blood PMN count  8.4±7.2 9.7±7.9 11.4±7.5 
% PMNs in BALF 69.7±2 (n=6) 73.7±11.1 (n=10) 59.8±2 (n=3) 
Etiology of ARDS Community acquired 
pneumonia, 
neutropenic sepsis, 
fresh water drowning, 
liver failure post 
transplant donation, 
ethylene glycol 
poisoning 
Community acquired 
pneumonia, aspiration 
pneumonia, 
neutropenic sepsis  
Community acquired 
pneumonia, aspiration 
pneumonia, 
neutropenic sepsis 
Juss et al. 2015
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ARDS neutrophils have a distinct phenotype and are resistant to phosphoinositide 3-
kinase inhibition 
 
Juss JK, House D, Amour A, Begg M, Herre J, Storisteanu DML, Hoenderdos K, Bradley G, 
Lennon M, Summers C, Hessel EM, Condliffe AM, Chilvers ER. 
 
Online Data Supplement 
 
Supplementary Figure 1 
Flowchart showing the precise details of the number of subjects included in each assay. 
 
Supplementary Figure 2 
Inflammatory markers in the BALF of patients with ARDS 
The concentration of key inflammatory mediators, were measured in control (n = 10) and 
ARDS (n = 18) BALF supernatants either by ELISA kit or an electrochemical luminescence 
immunoassay MesoScale Discovery (MSD) multiplex. S1(i) shows a heatmap representation 
of BALF markers in control subjects (C01-C10) vs ARDS patients (A01-18) without 
correction for BALF total protein, and S1(ii) shows a heatmap representation of the identical 
samples after correction for BALF total protein content (* P<0.05, ** P<0.01, ***P<0.001). 
 
Supplementary Figure 3 
Heat map of the transcriptomic changes in HV and ARDS blood PMNs 
A. Immune response.  B. Apoptosis.  C. Cytoskeletal remodelling.  D. Mucin production.  (n) 
= 12 for both groups. 
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Supplementary Figure 4 
The genes altered greater than 5-fold in ARDS neutrophils compared to HV neutrophils 
Negative values indicate a decrease in relative gene expression, while positive values indicate 
an increase in relative gene expression.  Bars highlighted in red where also altered in HV 
PMNs incubated with GM-CSF (fold change>1.5, p<0.05, (n) = 12 for all groups).  
 
Supplementary Figure 5 
The genes altered greater than 5-fold in ARDS neutrophils compared to HV neutrophils 
Negative values indicate a decrease in relative gene expression, while positive values indicate 
an increase in relative gene expression.  Bars highlighted in green were also altered in HV 
PMNs incubated with a pan-PI3K inhibitor (fold change>1.5, p<0.05, (n) = 12 for all groups).  
 
Supplementary Table 2 
Tables (i)-(vi) provide the full data set for blood and BALF cytokine values for HVs and 
ARDS patients.  For the BALF samples these are given both corrected and uncorrected for 
total protein content. 
 
Supplementary Table 3 
A comprehensive list of all 1319 significantly altered genes (fold change > 1.5; unadjusted p-
value < 0.05; false discovery rate q-value < 0.05) identified by the comparison of freshly 
isolated ARDS bloodPMNs with HV bloodPMNs using Affymetrix mRNA transcriptomic 
analysis. 
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